IP Library Granted Patent US 10,640,517
Granted Patent B2
US 10,640,517 · App. 16/054,512 · Granted May 5, 2020

Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

Inventors: Venkateshwar Rao Gummadi (Bangalore, IN); Susanta Samajdar (Bangalore, IN)
Assignee: Aurigene Discovery Technologies Limited
C07D513/04C07D498/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,640,517
App. No.
16/054,512
Granted
May 5, 2020
Kind
B2
Abstract

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X 1 , X 2 , X 3 , R 1 , R 3 , ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Claims (483)

1. A method of making a compound of formula (I) or a pharmaceutically acceptable salt thereof, according to the following scheme:

wherein:

M is

L is NH 2 ;

X 1 and X 3 independently are CH or N; X 2 is CR 2 or N, provided one and not more than one of X 1 , X 2 or X 3 is N;

A is O or S;

Y is —CH 2 — or O;

Z is aryl or heterocyclyl;

R 1 , at each occurrence, is independently halo or optionally substituted heterocyclyl, wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl or —NR a R b ;

R 2 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or —NR a R b , wherein the substituent is alkyl, amino, halo or hydroxyl;

R 3 , at each occurrence, is alkyl or hydroxyl;

R a and R b are independently hydrogen, alkyl, acyl, or heterocyclyl;

m and n are independently 0, 1 or 2;

p is 0 or 1;

Q 1 is N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI) or a salt thereof, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU);

Q 2 is hydroxybenzotriazole (HOBT) or is absent;

B is diisopropylethylamine (DIPEA) or trimethylamine (TEA); and

Sv is dimethylformamide.

2. The method of claim 1 , wherein

A is O or S;

Y is —CH 2 — or O;

Z is aryl or heterocyclyl;

R 1 , at each occurrence, is independently halo or optionally substituted heterocyclyl, wherein the substituent is alkyl, aminoalkyl, halo, or NR a R b ; where R a and R b are independently hydrogen, alkyl, or heterocyclyl;

R 2 is hydrogen, cycloalkyl, heterocyclyl or NR a R b ;

m is 0; and

n is 1.

3. The method of claim 1 , wherein

A is O or S;

Y is —CH 2 — or O;

Z is aryl or heterocyclyl;

R 1 , at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl or NR a R b ; where R a and R b are independently hydrogen, alkyl, or heterocyclyl;

R 2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl or NR a R b , where the substituent is selected from amino, halo or hydroxyl;

‘m’ and ‘n’ are independently 0, 1 or 2; and

‘p’ is 0 or 1.

4. The method of claim 1 , wherein the group

5. The method of claim 1 , wherein the compound of formula (I) is a compound of formula (IA):

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein

A is O or S;

Y is —CH 2 — or O;

R 1 , at each occurrence, is independently halo or optionally substituted heterocyclyl, wherein the substituent is alkyl, aminoalkyl, halo, or NR a R b ; where R a and R b are independently hydrogen, alkyl, or heterocyclyl;

R 2 is hydrogen, cycloalkyl, heterocyclyl or NR a R b ;

m is 0; and

n is 1.

7. The method of claim 5 , wherein

A is O or S;

Y is —CH 2 — or O;

R 1 , at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl or NR a R b ; where R a and R b are independently hydrogen, alkyl, or heterocyclyl;

R 2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl or NR a R b , where the substituent is selected from amino, halo or hydroxyl; and

‘m’ and ‘n’ are independently 0, 1 or 2.

8. The method of claim 1 , wherein the compound of formula (I) a compound of formula (IB):

or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein

A is O or S;

Y is —CH 2 — or O;

R 1 , at each occurrence, is independently halo or optionally substituted heterocyclyl, wherein the substituent is alkyl, aminoalkyl, halo, or NR a R b ; where R a and R b are independently hydrogen, alkyl, or heterocyclyl;

R 2 is hydrogen, cycloalkyl, heterocyclyl or NR a R b ; and

n is 1.

10. The method of claim 8 , wherein

A is O or S;

Y is —CH 2 — or O;

R 1 , at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl or NR a R b ; where R a and R b are independently hydrogen, alkyl, or heterocyclyl; and

R 2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl or NR a R b , where the substituent is selected from amino, halo or hydroxyl.

11. The method of claim 1 , wherein the compound of formula (I) is a compound of formula (IC):

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein

Q 1 is EDCI or a salt thereof; and

Q 2 is HOBT.

13. The method of claim 1 , wherein

Q 1 is HATU; and

Q 2 is absent.

14. The method of claim 1 , wherein the method further comprises a purification step.

15. The method of claim 14 , wherein the purification step comprises column chromatography, preparative thin layer chromatography, or high performance liquid chromatography.

16. The method of claim 1 , wherein the method further comprises a deprotection step.

17. The method of claim 16 , wherein the deprotection step comprises contacting the reaction mixture with a deprotection agent, wherein the deprotection agent is methanolic hydrochloric acid or tetrabutylammonium fluoride (TBAF).

18. The method of claim 1 , wherein the compound of formula (I) is selected from:

Example No

IUPAC name

1.

6′-amino-N-(2-morpholinooxazolo[4,5-b]pyridin-6-yl)-[2,3′-bipyridine]-6-

carboxamide;

2.

6′-amino-N-(5-cyclopropyl-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-[2,3′-

bipyridine]-6-carboxamide hydrochloride;

3.

N-(5-cyclopropyl-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-

yl)oxazole-4-carboxamide hydrochloride;

4.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-

yl)picolinamide hydrochloride;

5.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-

yl)oxazole-4-carboxamide;

6.

N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-

yl)picolinamide;

7.

2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

8.

6-chloro-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-

yl)picolinamide;

9.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-6-(1-methyl-1H-pyrazol-4-

yl)picolinamide;

10.

2-(2-chloropyridin-4-yl)-N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-

yl)oxazole-4-carboxamide;

11.

(S)-2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(pyrrolidin-3-ylamino)oxazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

12.

6′-amino-N-(2-morpholinooxazolo[5,4-b]pyridin-5-yl)-[2,3′-bipyridine]-6-

carboxamide;

13.

6′-amino-N-(2-morpholinothiazolo[4,5-c]pyridin-6-yl)-[2,3′-bipyridine]-6-

carboxamide;

14.

6′-amino-N-(2-morpholinothiazolo[5,4-b]pyridin-5-yl)-[2,3′-bipyridine]-6-

carboxamide;

15.

2-(2-methylpyridin-4-yl)-N-(2-morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-

carboxamide;

16.

6′-amino-N-(2-morpholinothiazolo[4,5-b]pyridin-6-yl)-[2,3′-bipyridine]-6-

carboxamide;

17.

N-(2-morpholinothiazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-yl)picolinamide;

18.

3-(4-(aminomethyl)piperidin-1-yl)-5-fluoro-N-(2-morpholinothiazolo[4,5-b]pyridin-

6-yl)benzamide;

19.

2-(4-(aminomethyl)piperidin-1-yl)-5-fluoro-N-(2-morpholinothiazolo[4,5-b]pyridin-

6-yl)benzamide;

20.

2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

21.

N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-

yl)picolinamide;

22.

N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-

yl)picolinamide;

23.

N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-

yl)oxazole-4-carboxamide;

24.

N-(2,5-dimorpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-

carboxamide;

25.

N-(5-(4-methylpiperazin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

26.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(6-methoxypyridin-3-

yl)oxazole-4-carboxamide;

27.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-3-

yl)oxazole-4-carboxamide;

28.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-hydroxypyridin-3-

yl)oxazole-4-carboxamide;

29.

2-(2-hydroxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

30.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(6-hydroxypyridin-3-

yl)oxazole-4-carboxamide;

31.

2-(2-methoxypyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

32.

2-(2-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

33.

2-(3-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

34.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(3-methylpyridin-4-

yl)oxazole-4-carboxamide;

35.

2-(6-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

36.

6-(1-methyl-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-

b]pyridin-6-yl)picolinamide;

37.

N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(6-methylpyridin-3-

yl)oxazole-4-carboxamide;

38.

(S)-N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

39.

(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

40.

(R)-N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

41.

(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

42.

(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

43.

(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-

b]pyridin-6-yl)picolinamide;

44.

(S)-6-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-

b]pyridin-6-yl)picolinamide;

45.

(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

46.

(S)-N-(5-cyclopropyl-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(3-

hydroxypyrrolidin-1-yl)oxazole-4-carboxamide;

47.

(S)-2-(3-aminopyrrolidin-1-yl)-N-(5-cyclopropyl-2-morpholinooxazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

48.

2-(2-methylpyridin-4-yl)-N-(5-(piperidin-1-yl)-2-(pyrrolidin-1-yl)oxazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride;

49.

N-(2-(2,6-dimethylmorpholino)-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;

50.

N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-6-(1-methyl-1H-pyrazol-4-

yl)picolinamide hydrochloride;

51.

6-(1-methyl-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-

b]pyridin-6-yl)picolinamide;

52.

N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-3-

yl)oxazole-4-carboxamide hydrochloride;

53.

N-(2-((2S,6R)-2,6-dimethylmorpholino)-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-

yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;

54.

2-(2-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

55.

2-(2-hydroxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

56.

N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methoxypyridin-4-

yl)oxazole-4-carboxamide;

57.

2-(6-methoxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

58.

2-(2-methoxypyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

59.

(S)-N-(5-(3-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

60.

2-(6-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

61.

2-(3-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

62.

(S)-6-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-

b]pyridin-6-yl)picolinamide;

63.

(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-

b]pyridin-6-yl)picolinamide;

64.

(S)-6-(3-aminopyrrolidin-1-yl)-N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-

yl)picolinamide;

65.

(S)-N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-6-(3-hydroxypyrrolidin-1-

yl)picolinamide;

66.

(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

67.

(S)-N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

68.

(S)-2-(3-aminopyrrolidin-1-yl)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

69.

N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-

yl)oxazole-4-carboxamide;

70.

(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

71.

(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

72.

(S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-6-(3-

hydroxypyrrolidin-1-yl)picolinamide;

73.

(S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(3-

hydroxypyrrolidin-1-yl)oxazole-4-carboxamide;

74.

(S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-6-(1-(2-

hydroxypropyl)-1H-pyrazol-4-yl)picolinamide;

75.

(S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(1-(2-

hydroxypropyl)-1H-pyrazol-4-yl)oxazole-4-carboxamide;

76.

N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(6-

methoxypyridin-3-yl)oxazole-4-carboxamide;

77.

(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(6-

methoxypyridin-3-yl)oxazole-4-carboxamide;

78.

(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(6-

methoxypyridin-3-yl)oxazole-4-carboxamide;

79.

(S)-N-(5-(azetidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-6-(3-

hydroxypyrrolidin-1-yl)picolinamide;

80.

N-(5-(3-hydroxyazetidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

81.

(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)thiophene-2-carboxamide;

82.

(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide;

83.

(S)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

84.

N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide

85.

(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

86.

N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide;

87.

N-(5-(azetidin-1-yl)-2-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

88.

2-(2-methylpyridin-4-yl)-N-(2-(piperidin-1-yl)-5-(pyrrolidin-1-yl)thiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

89.

2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(pyrrolidin-1-yl)thiazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

90.

5-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-

6-yl)furan-2-carboxamide;

91.

N-(5-(azepan-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-

yl)oxazole-4-carboxamide;

92.

2-(2-aminopyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-

yl)oxazole-4-carboxamide hydrochloride;

93.

N-(5-(azetidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-

yl)oxazole-4-carboxamide;

94.

(R)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

95.

(R)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide;

96.

(S)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-

yl)thiazolo[4,5-b]pyridin-6-yl)picolinamide

97.

N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide

98.

N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride

99.

N-(5-(1-methyl-1H-pyrazol-4-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

100.

N-(5-(3-fluorophenyl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-

4-yl)oxazole-4-carboxamide;

101.

N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide;

102.

N-(5-(3-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide;

103.

(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(6-

methoxypyridin-3-yl)oxazole-4-carboxamide;

104.

N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

105.

(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(6-

methoxypyridin-3-yl)oxazole-4-carboxamide;

106.

N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(6-

methoxypyridin-3-yl)oxazole-4-carboxamide;

107.

(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide;

108.

(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)thiophene-2-carboxamide;

109.

N-(5-(azetidin-1-yl)-2-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

110.

2-(2-methylpyridin-4-yl)-N-(2-(piperidin-1-yl)-5-(pyrrolidin-1-yl)oxazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

111.

5-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-

6-yl)furan-2-carboxamide;

112.

N-(5-(azetidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-

yl)oxazole-4-carboxamide;

113.

2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(pyrrolidin-1-yl)oxazolo[4,5-b]pyridin-

6-yl)oxazole-4-carboxamide;

114.

N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide;

115.

(R)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-5-(2-

methylpyridin-4-yl)furan-2-carboxamide;

116.

N-(5-(furan-3-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-

yl)oxazole-4-carboxamide;

117.

N-(5-(3-fluoropiperidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

118.

N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

119.

N-(5-(4-fluoropiperidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

120.

(S)-N-(5-(3-aminopiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

121.

2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(1H-pyrazol-4-yl)thiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide;

122.

N-(5-(6-fluoropyridin-3-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

123.

N-(5-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)-2-morpholinothiazolo[4,5-b]pyridin-

6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;

124.

N-(2-(3-hydroxypiperidin-1-yl)-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

125.

2-(2-acetamidopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-

morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide;

126.

N-(2-(3-hydroxypiperidin-1-yl)-5-(4-hydroxypiperidin-1-yl)thiazolo[4,5-b]pyridin-6-

yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;

127.

2-(2-acetamidopyridin-4-yl)-N-(5-(3-hydroxypiperidin-1-yl)-2-

morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide;

128.

2-(2-aminopyridin-4-yl)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride;

129.

5-(2-aminopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-

b]pyridin-6-yl)furan-3-carboxamide hydrochloride;

130.

2-(2-aminopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride;

131.

2-(2-aminopyridin-4-yl)-N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-

b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride;

132.

N-(5-(2-fluoropyridin-4-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide;

133.

N-(5-(4-fluoropiperidin-1-yl)-2-(3-hydroxypiperidin-1-yl)thiazolo[4,5-b]pyridin-6-

yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;

134.

N-(5-(4-aminopiperidin-1-yl)-2-(3-hydroxypiperidin-1-yl)thiazolo[4,5-b]pyridin-6-

yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride; and

135.

N-(5-(2-hydroxypyridin-4-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-

methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Mar 3, 2025
From: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
To: AURIGENE ONCOLOGY LIMITED
Reel/Frame 070378/0823 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2018
From: GUMMADI, VENKATESHWAR RAO; SAMAJDAR, SUSANTA
To: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
Reel/Frame 047266/0795 →
Priority Claims (2)
IN 158/CHE/2014 · Jan 13, 2014 · national
IN 3000/CHE/2014 · Jun 20, 2014 · national
Continuity (3)
Continuation 15667173 · Aug 2, 2017
Continuation 15111000
Related Publication 20180370988A1 · Dec 27, 2018
Cited By (1)
US 12,410,193